Patients prescribed glucagon-like peptide-1 (GLP-1) receptor agonists for Type 2 diabetes face a 48% higher rate of developing smell and taste disturbances compared to those on other antidiabetic medications. A retrospective cohort study published in JAMA Otolaryngology–Head & Neck Surgery by J. Zontag and N. Zontag found that these sensory issues were consistently higher among GLP-1 users throughout a follow-up period of up to two years.
How does GLP-1 therapy impact sensory perception?
Data analyzed from electronic health records between 5th December 2017 and 20th April 2026 reveal a clear disparity in sensory outcomes. Researchers tracked 876,948 patients, split equally between a GLP-1 cohort and a control group taking alternative diabetes treatments. According to the study, those in the GLP-1 group experienced an 81% higher rate of smell disturbances and a 52% higher rate of taste disturbances than the control group.
What are the clinical implications for patients?
The findings suggest that researchers called for the closer monitoring of patients taking GLP-1s, alongside greater public health awareness of the medication’s side effects. Currently, the underlying pathways and mechanisms that may cause the disturbances remain unknown, prompting calls for further scientific investigation to validate these findings and identify the pathways involved.
Comparison of sensory disturbance rates
| Disturbance Type | Increased Rate (GLP-1 vs. Control) |
|---|---|
| Smell Disturbances | 81% |
| Taste Disturbances | 52% |
Future trends in diabetes medication monitoring
Future research, the authors reported, is necessary to validate the findings and analyse the underlying pathways and mechanisms that may cause the disturbances.
Frequently Asked Questions
Are smell and taste disturbances common with all diabetes drugs?
No. The study by J. Zontag and N. Zontag specifically highlights a 48% higher rate of these disturbances in patients using GLP-1 receptor agonists compared to those on other types of antidiabetic medications.
What should I do if I experience sensory changes while on GLP-1s?
Researchers recommend the closer monitoring of patients taking GLP-1s.
Is there a known biological cause for these sensory issues?
Not yet. The study identifies a link between the medication and the disturbances, but researchers state that further study is required to analyse the underlying pathways and mechanisms that may cause the disturbances.
Have you or someone you know experienced changes in smell or taste while managing Type 2 diabetes? Share your experience in the comments below or subscribe to our newsletter for the latest updates on diabetes research and patient care.
